Skip to content

Tetramethylpyrazine alleviates cerebral ischemia-reperfusion injury via NRF2/HO-1/GPX4-mediated ferroptosis inhibition.

Jul 2026 · Tissue & Cell · Vol 104 Pt 1, pp. 103798 · 0 citations · 46 references
Medicine

TL;DR

TMP exerts neuroprotective effects in mitigating CIRI, which is associated with the regulation of ferroptosis and involves activation of the NRF2/HO-1/GPX4 pathway.

Abstract

Background

Cerebral ischemia-reperfusion injury (CIRI) is a devastating neurological disorder involving autophagy, oxidative stress, and ferroptosis. Tetramethylpyrazine (TMP) has demonstrated potential pharmacological efficacy in antiplatelet aggregation, antithrombotic effects, vasodilation, and neuroprotection.

Purpose

This study aimed to determine the therapeutic efficacy of TMP in treating CIRI and to investigate whether TMP could improve CIRI by inhibiting ferroptosis through activation of the nuclear factor erythroid 2-related factor 2 (NRF2)/heme oxygenase 1 (HO-1)/glutathione Peroxidase 4 (GPX4) pathway in rats.

Methods

We established MCAO/R rat models and OGD/R-treated HT22 cell models to evaluate the neuroprotective effects of TMP, employed network pharmacology and metabolomics to predict key signaling pathways, and assessed ferroptosis-related changes via biochemical assays, Western blotting, and transmission electron microscopy.

Results

In vivo studies showed that TMP improved neurological scores, reduced infarct volume, and mitigated pathological features following MCAO/R. Network pharmacology and metabolomics revealed that TMP indirectly activated NRF2-mediated antioxidant responses while regulating glycerophospholipid metabolism and glycine/serine/threonine metabolism pathways. Mechanistically, TMP reduced oxidative stress markers, restored antioxidant capacity, and upregulated NRF2, HO-1, GPX4 and SLC7A11 expression, while the NRF2 inhibitor ML385 reversed these effects. These findings were further corroborated by in vitro experiments in OGD/R-exposed HT22 neurons, where TMP enhanced cell viability, attenuated lipid peroxidation and iron accumulation, and preserved mitochondrial ultrastructure, with ML385 partially reversing the protective effects.

Conclusion

TMP exerts neuroprotective effects in mitigating CIRI, which is associated with the regulation of ferroptosis and involves activation of the NRF2/HO-1/GPX4 pathway.

View source

Similar papers

Open access Sep 2026

Remimazolam attenuates myocardial ischemia/reperfusion injury by inhibiting ferroptosis involving the AKT/SLC7A11/GPX4 axis

Remimazolam (RMZ) is an ultra-short-acting sedative anesthetic that provides protection against cerebral and hepatic ischemia/reperfusion injury. However, its potential cardioprotective effect in myocardial ischemia reperfusion injury (MIRI) remains to be fully elucidated. The present study investigated the hypothesis...

Xi-Yuan Chen, Jiang-Hong Zhao, Xing-Tong He et al. · 0 citations
Jul 2026

Kaempferol alleviates myocardial ischemia-reperfusion injury by activating the Nrf2/GPX4 signaling pathway to inhibit ferroptosis.

It is demonstrated that kaempferol ameliorates MIRI by activating Nrf2/GPX4-related antioxidant signaling, thereby inhibiting ferroptosis, attenuating apoptosis, reducing myocardial structural damage, and ultimately preserving cardiac function.

Xuan Tang, Weiguang Zou, Tao Peng et al. · 0 citations
Aug 2026

4-Octyl itaconate attenuates cerebral ischemia reperfusion injury by mitigating mitochondrial dysfunction mediated neuronal apoptosis and ferroptosis via the Nrf2/HO-1/SLC7A11/GPX4 axis.

It is suggested that 4-OI confers Neuroprotection against I/R injury by activating Nrf2 pathway, reducing oxidative stress, and suppressing ferroptotic and apoptotic cell death.

Chandan Chauhan, Ravinder K. Kaundal · 0 citations
Aug 2026

Melatonin attenuates ferroptosis-associated injury through modulation of the thioredoxin-interacting protein/thioredoxin-1/glutathione peroxidase 4 pathway after neonatal hypoxic ischemic brain damage.

Mel attenuates acute neonatal HIBD and reduces ferroptosis-associated neuronal injury, potentially involving modulation of the TXNIP/Trx-1/GPX4 pathway.

You-Cheng Qin, Pei-Lun Xiao, Xin-Yu Zhang et al. · 0 citations
Open access Sep 2026

Echinocystic acid alleviates cerebral ischemia-reperfusion injury through PPARγ-dependent modulation of microglial polarization and pyroptotic signaling.

Findings indicate that Echinocystic acid protects against CIRI, at least in part, through a PPARγ-dependent mechanism involving promotion of microglial M2 polarization and attenuation of NLRP3/Caspase-1/GSDMD-associated pyroptotic signaling, highlighting the therapeutic potential of EA in CIRI.

Yi Zou, Hui Zhang, Jian-Xia Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.